# A Study to Learn About the Outcomes Between Study Medicines, Enzalutamide and Darolutamide Among Men With Metastatic Castration Sensitive Prostate Cancer (mCSPC)

> **NCT07779590** · — · ACTIVE_NOT_RECRUITING · sponsor: **Pfizer** · enrollment: 4700 (estimated)

## Conditions studied

- Metastatic Castration Sensitive Prostate Cancer (mCSPC)

## Interventions

- **DRUG:** darolutamide plus androgen deprivation therapy
- **DRUG:** Enzalutamide plus androgen deprivation therapy

## Key facts

- **NCT ID:** NCT07779590
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-08-19
- **Primary completion:** 2026-11-15
- **Final completion:** 2026-11-15
- **Target enrollment:** 4700 (ESTIMATED)
- **Last updated:** 2026-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07779590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07779590, "A Study to Learn About the Outcomes Between Study Medicines, Enzalutamide and Darolutamide Among Men With Metastatic Castration Sensitive Prostate Cancer (mCSPC)". Retrieved via MORVS 2026-11-22 from https://api.morvs.ai/clinical/NCT07779590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*
